Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Greed has gripped the market, but that doesn't mean you can't invest wisely. Even today, anti-bubble blue-chip bargains like Bristol-Myers Squibb Company are hitting new 52-week lows. Bristol-Myers is an A+ rated 3.7% yielding pharma titan with a strong pipeline, rivers of free cash flow, and the 7th largest pharma R&D budget in the world.

Bristol-Myers: Potentially Set To Soar And Too Cheap To Ignore

Apple

AbbVie

Arbor Realty Trust

Abbott Labs

Archer-Daniels-Midland Company

Aflac

Ameriprise Financial

Amazon

American Express

Bank of America

Becton, Dickinson and Co.

Blackrock Inc

Citigroup

Cardinal Health

Caterpillar

Cisco Systems

CVS Health

Chevron

Disney

Digital Realty Trust

Duke Energy

Emerson Electric

Enterprise Products Partners

Eaton

In 2015, I started publishing updates regarding my dividend growth portfolio, and I keep doing so every quarter. This is part of being transparent with my readers, so they can see what I hold and its correlation with my writing. This article summarizes Q2 of 2023 and focuses on goals, current holdings, allocation, sales, and buys.

My Dividend Growth Portfolio - Q2 2023 Summary

Bristol Myers Squibb (BMY) closed at $62.28 in the latest trading session, marking no change from the prior day.

Bristol Myers Squibb (BMY) Flat As Market Gains: What You Should Know

Merck

The U.S. Chamber of Commerce asked a judge to stop the federal government from putting into effect a law that will allow Medicare to negotiate the prices of some prescription drugs.

Big Pharma Ramps Up Fight Against Medicare Price Negotiations

Domino's Pizza

The S&P 500 and Nasdaq saw a significant rally in the first half of 2023, led by technology companies, with the top three performing sectors being Information Technology, Communication Services, and Consumer Discretionary. Given the top heavy rally in the first half, we go value hunting in today's piece and look at three quality dividend stocks primed to outperform in the second half. There is a lot of uncertainty in the back half of the year, which could have investors switch from risk-on assets to more defensive sectors.

3 Dividend Stocks Poised To Outperform The Rest Of 2023

Bristol Myers (BMY) meets its dual primary endpoint in the late-stage expansion study of Opdivo for the treatment of unresectable or metastatic urothelial carcinoma.

Bristol Myers (BMY) Reports Positive Data From Urothelial Cancer Study

Bristol-Myers Squibb Co said on Tuesday its drug in combination with chemotherapy met a dual main goal in a late-stage trial in patients with a type of bladder cancer.

Bristol Myers' bladder cancer drug meets goal in late stage sub-study

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for.

Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial

Evotec SE

EVOTEC AND BRISTOL MYERS SQUIBB ENTER EXCLUSIVE GLOBAL LICENCE AGREEMENT FOR SELECTED PROGRAMMES DEVELOPED AND PROGRESSED IN THE COLLABORATION SELECTED PROGRAMMES FURTHER STRENGTHEN THE PROGRAMME PIPELINE OF NEURODEGENERATION ASSETS EVOTEC RECEIVES $ 40 M PAYMENT AND IS ELIGIBLE TO EARN PERFORMANCE MILESTONE PAYMENTS, AS WELL AS TIERED ROYALTIES UP TO LOW DOUBLE-DIGIT PERCENTAGES ON PRODUCT SALES HAMBURG, GERMANY / ACCESSWIRE / July 11, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that Bristol Myers Squibb Company (NYSE:BMY) has exercised its option to enter into an exclusive global licence agreement. The licence covers selected late-stage discovery programmes that were developed and progressed within the collaboration.

Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience Partnership

Bristol Myers Squibb is an attractive investment due to its consistent growth in sales and earnings per share, along with a generous dividend and aggressive buybacks. Despite facing challenges such as intense competition and high debt levels, the company's pipeline of over 50 drugs and therapies offers significant long-term growth opportunities. The company's low valuation presents a great entry point for long-term investors.

Bristol Myers Squibb Is A Buy At Current Valuation

Bristol-Myers Squibb Company is battling the loss of exclusivity of Revlimid with some new product growth engines. This is badly needed as more expirations are due this decade. The situation is tough from a growth perspective, but overall valuations here are extremely non-demanding, making me gradually more upbeat here.

Bristol-Myers Squibb: Battling Exclusivity Headwinds

BMY is generating solid underlying business growth and continues to buy back shares which drives EPS upside. BMY offers a dividend yield of 3.6% at current prices and raises its dividend regularly.

Bristol Myers Squibb: Attractive Buying Opportunity

HCA Healthcare

There is more to the comparison, and in the sections below, we discuss why we believe BMY stock will offer higher returns than HCA stock in the next three years.

Which Stock Is A Better Healthcare Pick – Bristol Myers Squibb Or HCA?

Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?

Johnson & Johnson

AbbVie is a Dividend King with a high yield. Bristol Myers Squibb is an underrated bargain.

3 Spectacular Dividend Stocks to Buy in July

Bristol Myers' (BMY) Opdivo, in combination with chemotherapy, gains European Commission approval for neoadjuvant treatment of non-small cell lung cancer, offering new hope for reducing recurrence risk.

Bristol Myers' (BMY) Opdivo With Chemo Gets EC Nod for NSCLC

Amgen

Pfizer

Some of the biggest names in healthcare are on sale right now. J&J, AbbVie, Bristol Myers, Amgen, and Pfizer all trade at low valuations.

5 High-Yielding Dividend Stocks That Are Bargain Buys

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--BMS Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung.

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expression ≥1%

making Bristol Myers Squibb even more interesting is the fact that in trading on Wednesday, shares of BMY entered into oversold territory

Bristol Myers Squibb Enters Oversold Territory

Funds raised will be used to demonstrate clinical validation and proof-of-concept in t(4;14) multiple myeloma with KTX-1001 monotherapy and KTX-1001 combination regimens with existing standard-of-care agents CAMBRIDGE, Mass., June 28, 2023 /PRNewswire/ -- K36 Therapeutics ("K36"), a privately held clinical-stage biotech company developing KTX-1001, an investigational small molecule methyltransferase inhibitor of multiple myeloma SET (MMSET) domain, today announced a $70M Series B financing.

K36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class Inhibitor of MMSET for Treatment of Multiple Myeloma Patients with Genetic Translocation (4;14)

Bristol Myers (BMY) receives EC approval for Camzyos for treating symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (HCM) in adult patients.

Bristol Myers (BMY) Heart Drug Camzyos Wins EC Approval

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--BMS Receives European Commission Approval of CAMZYOS® (mavacamten), for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM).

Bristol Myers Squibb Receives European Commission Approval of CAMZYOS® (mavacamten), for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)

Thermo Fisher Scientific

CVS should benefit from rising demand for health insurance and medications. Thermo Fisher Scientific is a key provider of medical supplies to the drug industry.

3 Healthcare Stocks That Are Too Cheap to Ignore

International Paper

SPDR S&P Regional Banking ETF

M&T Bank

Truist Financial

WestRock

Several sectors are trading at discounts to the S&P 500. The stocks might have some downside, but their prices account for a considerable amount of risk.

The Market Rally Made Stocks Expensive. These Are Still Cheap.

Black Hills

Crown Castle International

Evergy Inc

Home Depot

Lowe's

Spire

Sempra Energy

Tractor Supply

This monthly series ranks a selection of dividend growth stocks in Dividend Radar and presents the ten top-ranked stocks for consideration and possible investment. The stocks were selected based on quality, safety, valuation, and yield/growth criteria, with a focus on high-quality, discounted stocks with safe dividends likely to deliver annualized returns of at least 8%. I rank stocks by sorting them in descending order by quality score and using tie-breaking metrics where necessary.

News for Bristol-Myers Stock (BMY)